List view / Grid view
In this issue you can find articles discussing the supply chain implications of Trump's 'Buy American' order, guidance on how to identify and justify starting materials for regulatory approval by both the EMA and FDA, as well as some of the latest developments in oral biologic drug delivery techniques. Also…
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
Researchers have shown that mucoadhesive buccal films containing simvastatin inclusion complex and drug mixed micelles can improve the drug's bioavailability.
Dolutegravir plus lamivudine was as effective at suppressing HIV-1 in adult trial participants as a three-drug regimen, dolutegravir plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).
Researchers have developed a novel tablet formulation of ibandronate which increases the oral bioavailability of the drug by releasing it from a hydrogel raft formed in the stomach.
Watson-Marlow Fluid Technology Group discusses how the biopharma community is coming together to solve the global vaccine development challenge.
A Phase I clinical trial to test an intranasal COVID-19 vaccine spray has been given regulatory approval in China and is expected to begin in November.
A clinical trial has shown that antibiotics administered orally are just as effective at killing Pseudomonas aeruginosa in cystic fibrosis patients as intravenous antibiotics.
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
This whitepaper explores critical factors for over-encapsulation success. DBcaps® capsules offer a convenient option for blinding in clinical trials.
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
Michael Sassano from Somai Pharmaceuticals and Solaris Farms discusses the US and European markets for growing and extracting cannabinoids for the pharmaceutical industry.
Preliminary data from Phase I/II trails evaluating the vaccine reveal 100 percent of participants had a humoral and cellular response, with no serious adverse events reported.
AUC was used to probe the effect of insulin concentration and the zinc chelating agent EDTA on monomer, dimer, and hexamer formation of USP Human Insulin Standard.
The X 3 is a breakthrough in the small-scale and mid-range tablet press market segment and the latest advancement from KORSCH.
